Biogen Inc. (BIIB)
NASDAQ: BIIB · Real-Time Price · USD
140.98
+0.43 (0.31%)
At close: Jan 21, 2025, 4:00 PM
141.55
+0.57 (0.40%)
After-hours: Jan 21, 2025, 6:47 PM EST
Biogen Stock Forecast
Stock Price Forecast
The 24 analysts with 12-month price forecasts for Biogen stock have an average target of 234.79, with a low estimate of 138 and a high estimate of 342. The average target predicts an increase of 66.54% from the current stock price of 140.98.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Biogen stock from 26 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
---|---|---|---|---|---|---|
Strong Buy | 7 | 7 | 8 | 7 | 6 | 6 |
Buy | 10 | 10 | 8 | 8 | 7 | 6 |
Hold | 6 | 6 | 8 | 10 | 13 | 14 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 23 | 23 | 24 | 25 | 26 | 26 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Wells Fargo | Wells Fargo | Hold Maintains $190 → $165 | Hold | Maintains | $190 → $165 | +17.04% | Jan 10, 2025 |
Truist Securities | Truist Securities | Strong Buy Maintains $302 → $220 | Strong Buy | Maintains | $302 → $220 | +56.05% | Jan 8, 2025 |
Piper Sandler | Piper Sandler | Buy → Hold Downgrades $315 → $138 | Buy → Hold | Downgrades | $315 → $138 | -2.11% | Jan 2, 2025 |
BMO Capital | BMO Capital | Buy → Hold Downgrades $230 → $164 | Buy → Hold | Downgrades | $230 → $164 | +16.33% | Dec 20, 2024 |
B of A Securities | B of A Securities | Hold Initiates $178 | Hold | Initiates | $178 | +26.26% | Dec 10, 2024 |
Financial Forecast
Revenue This Year
9.83B
from 9.84B
Decreased by -0.04%
Revenue Next Year
9.72B
from 9.83B
Decreased by -1.17%
EPS This Year
16.71
from 7.97
Increased by 109.72%
EPS Next Year
17.06
from 16.71
Increased by 2.06%
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | 10.2B | 11.0B | 11.4B | |||
Avg | 9.8B | 9.7B | 9.9B | |||
Low | 9.3B | 8.6B | 8.6B |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | 4.1% | 11.9% | 17.1% | |||
Avg | -0.0% | -1.2% | 2.1% | |||
Low | -5.8% | -12.8% | -11.8% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | 17.51 | 21.15 | 21.83 | |||
Avg | 16.71 | 17.06 | 18.14 | |||
Low | 15.82 | 14.24 | 14.14 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|---|
High | 119.7% | 26.5% | 28.0% | |||
Avg | 109.7% | 2.1% | 6.4% | |||
Low | 98.5% | -14.8% | -17.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.